Sze-chuan Suen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2133003/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	2.9	138
2	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	2.9	69
3	Chronic Disease Onset Among People Living with HIV and AIDS in a Large Private Insurance Claims Dataset. Scientific Reports, 2019, 9, 18514.	1.6	53
4	Forecasting trends in disability in a super-aging society: Adapting the Future Elderly Model to Japan. Journal of the Economics of Ageing, 2016, 8, 42-51.	0.6	48
5	Disease Control Implications of India's Changing Multi-Drug Resistant Tuberculosis Epidemic. PLoS ONE, 2014, 9, e89822.	1.1	24
6	Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India's public care system covering >100,000,000 inhabitants. BMC Public Health, 2014, 14, 418.	1.2	24
7	Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model. JHEP Reports, 2021, 3, 100367.	2.6	21
8	Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Health Care Management Science, 2018, 21, 632-646.	1.5	14
9	Cost-effectiveness of artificial intelligence monitoring for active tuberculosis treatment: A modeling study. PLoS ONE, 2021, 16, e0254950.	1.1	10
10	An Efficient, Noniterative Method of Identifying the Cost-Effectiveness Frontier. Medical Decision Making, 2016, 36, 132-136.	1.2	7
11	Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated crossâ€sectional data. Health Economics (United Kingdom), 2021, 30, 30-51.	0.8	6
12	Design of Incentive Programs for Optimal Medication Adherence in the Presence of Observable Consumption. Operations Research, 2022, 70, 1691-1716.	1.2	6
13	Risk stratification in compartmental epidemic models: Where to draw the line?. Journal of Theoretical Biology, 2017, 428, 1-17.	0.8	5
14	Costâ€effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus. Cancer Medicine, 2020, 9, 440-446.	1.3	5
15	How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. Current Alzheimer Research, 2021, 17, 819-822.	0.7	3
16	Matching Microsimulation Risk Factor Correlations to Cross-sectional Data: The Shortest Distance Method. Medical Decision Making, 2018, 38, 452-464.	1.2	2
17	Design of Incentive Programs for Optimal Medication Adherence. SSRN Electronic Journal, 2018, , .	0.4	2
18	Allocating outreach resources for disease control in a dynamic population with information spread. IISE Transactions, 2021, 53, 629-642.	1.6	1

#	Article	IF	CITATIONS
19	Optimizing diabetes screening frequencies for at-risk groups. Health Care Management Science, 2021, , 1.	1.5	1
20	Developing targeted HIV risk predictors for young black men who have sex with men: a two-city comparative study. International Journal of STD and AIDS, 2020, 31, 335-344.	0.5	0
21	Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. BMC Urology, 2022, 22, 76.	0.6	0